Log inSign up
Drew Moghanaki
25.8K posts
Image
user avatar
Drew Moghanaki
@DrewMoghanaki
MD, MPH, FASTRO - Lung Cancer Specialist & Endowed Thoracic Oncology Research Chair, UCLA | Co-Director, Lung Precision Oncology Pgm, VA Greater Los Angeles
Los Angeles, CA
uclahealth.org/radonc/drew-mo…
Joined April 2013
1,406
Following
13.6K
Followers
  • Pinned
    user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Nov 20, 2024
    Lung cancer needs to be prioritized as one of America’s top-5 public health problems. Learn how the VA understands this and is addressing it through a national initiative known as LPOP: spectrumnews1.com/ca/southern-ca…
    Image
    19K
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Feb 9, 2023
    The standard of care for stage IA NSCLC can now officially change. [Ref: CALGB 140503] #lcsm nejm.org/doi/full/10.10…
    Image
    80K
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    May 10, 2023
    BREAKING: A new randomized trial demonstrates the benefit of SBRT for patients with EGFR+ stage IV NSCLC. It demonstrates both PFS and OS benefits (n=62). 🇨🇳 #radonc @EGFRResisters @jillfeldman4 thegreenjournal.com/article/S0167-…
    Image
    46K
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    May 15, 2023
    I'd like to emphasize that @_ShankarSiva has set a new bar for preparing a talk. He used images derived using AI, and the transitions were simply spectacular. #ESTRO23 #radonc
    Image
    57K
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Jan 5, 2025
    Look no further to learn which battlefront needs the most help. Hint: it isn’t prostate cancer.
    Image
    45K
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Jun 30, 2022
    A new report from @_ShankarSiva shows why TOTAL METASTATIC ABLATION is preferred whenever feasible. #radonc 1/
    Image
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Oct 8, 2021
    Still don't believe in the power of cancer advocacy? This bill was just signed by our governor. It declares that it will soon be a CRIME for an insurance company in California to deny biomarker testing for stage III or IV cancer. #lcsm #radonc leginfo.legislature.ca.gov/faces/billText…
    Image
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Sep 7, 2025
    “Resectability depends on a state of mind” - @Mat_Guc …and society perspectives #WCLC25
    Image
    21K
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Dec 14, 2021
    The Timmerman Files are finally published, along with the confession "In all honesty, except for the spinal cord, all other limits for this original table were my educated guesses". #radonc doi.org/10.1016/j.ijro…
    Image
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Dec 27, 2024
    🫁 The PACIFIC-5 study results are finally available. They provide randomized data supporting consolidation Durvalumab for patients with stage III NSCLC treated with either concurrent or sequential chemoradiotherapy. #radonc #ESMOasia24
    Image
    17K
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Nov 12, 2021
    The next time that someone in the Ivory Tower perseverates over the value of studies that rely merely on a PFS signal, please share this slide that @jillfeldman4 created which sheds light on what patients often endure to get that PFS signal. #lcsm #radonc
    Image
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Oct 21, 2018
    As we’ve got a series of British speakers at #ASTRO18, a primer is needed for us Americans to understand why they really mean. 🇬🇧
    Image
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Dec 31, 2024
    🫁 SBRT has forever changed lung cancer treatment. With sub-millimeter accuracy, we now treat and even cure lung cancer in a single session. There is zero downtime with this treatment as there’s no need for anesthesia or even lidocaine. It’s just amazing. #radonc
    Image
    10K
  • user avatar
    Drew Moghanaki
    @DrewMoghanaki
    Jul 10, 2023
    I know at least a dozen radiation oncologists who have worried for decades that IMRT would increase the risk of secondary cancers compared to conventional 3DCRT. A SEER-linked Mediare study of 65,235 patients with at least 2 years of survival now tells us this. #radonc
    Image
    Image
    27K

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms of Service|Privacy Policy|Cookie Policy|Accessibility|Ads info|© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
Advertisement
Advertisement